mutLBSgeneDB |
Gene summary for NPR3 |
Gene summary |
Basic gene Info. | Gene symbol | NPR3 |
Gene name | natriuretic peptide receptor 3 | |
Synonyms | ANP-C|ANPR-C|ANPRC|C5orf23|GUCY2B|NPR-C|NPRC | |
Cytomap | UCSC genome browser: 5p13.3 | |
Type of gene | protein-coding | |
RefGenes | NM_000908.3, NM_001204375.1,NM_001204376.1,NM_024563.3, | |
Description | atrial natriuretic peptide clearance receptoratrial natriuretic peptide receptor 3atrial natriuretic peptide receptor type Catrionatriuretic peptide receptor Cguanylate cyclase Cnatriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic pep | |
Modification date | 20141207 | |
dbXrefs | MIM : 108962 | |
HGNC : HGNC | ||
Ensembl : ENSG00000113389 | ||
HPRD : 00167 | ||
Vega : OTTHUMG00000150316 | ||
Protein | UniProt: P17342 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_NPR3 | |
BioGPS: 4883 | ||
Pathway | NCI Pathway Interaction Database: NPR3 | |
KEGG: NPR3 | ||
REACTOME: NPR3 | ||
Pathway Commons: NPR3 | ||
Context | iHOP: NPR3 | |
ligand binding site mutation search in PubMed: NPR3 | ||
UCL Cancer Institute: NPR3 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for NPR3 |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | Y138 | Y138H | STAD | 3 | N110 | G109W | LUAD | 1 | D237 | D237Y | LUAD | 1 | E333 | F332S | LUAD | 1 | R211 | R211W | LUAD | 1 | M337 | S336F | SKCM | 1 | A161 | A159V | STAD | 1 | Y171 | Y171H | STAD | 1 | K208 | L209P | UCEC | 1 | Y204 | Y204C | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for NPR3 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | E333 | F332S | -1.485769 | R211 | R211W | -1.4801065 | Y171 | Y171H | -1.2384075 | K208 | L209P | -1.0530624 | Y138 | Y138H | -1.0166234 | M337 | S336F | -0.8709796 | Y204 | Y204C | -0.72483403 | D237 | D237Y | -0.37139464 | A161 | A159V | -0.31943553 | N110 | G109W | -0.3065982 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for NPR3 from PDB |
PDB ID | PDB title | PDB structure | 1JDN | Crystal Structure of Hormone Receptor |
Top |
Differential gene expression and gene-gene network for NPR3 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for NPR3 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0033578 | Prostatic Neoplasms | 1 | Biomarker |
umls:C0043094 | Weight Gain | 1 | Biomarker |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for NPR3 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Approved|investigational | DB04899 | Nesiritide | Biotech |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of NPR3 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
Top |
Conservation information for LBS of NPR3 |
Multiple alignments for P17342 in multiple species |
LBS | AA sequence | # species | Species | A141 | CEYAAAPVARL | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | A161 | SAGALAAGFQH | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | A162 | AGALAAGFQHK | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | D206 | ALVYSDDKLER | 1 | Homo sapiens | D206 | ALLYSDDKLER | 1 | Rattus norvegicus | D206 | VLVYSDDKLER | 1 | Bos taurus | D237 | SAYNFDETKDL | 2 | Rattus norvegicus, Bos taurus | D237 | SIYSFDETKDL | 1 | Homo sapiens | E137 | LGPVCEYAAAP | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | E170 | QHKDTEYSHLT | 2 | Rattus norvegicus, Bos taurus | E170 | QHKDSEYSHLT | 1 | Homo sapiens | E218 | CYFTLEGVHEV | 2 | Homo sapiens, Rattus norvegicus | E218 | CFFTLEGVHEV | 1 | Bos taurus | E222 | LEGVHEVFQEE | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | E333 | VKPEFEKFSME | 2 | Homo sapiens, Bos taurus | E333 | AKPEFEKFSME | 1 | Rattus norvegicus | F164 | ALAAGFQHKDT | 2 | Rattus norvegicus, Bos taurus | F164 | ALAAGFQHKDS | 1 | Homo sapiens | F215 | ERNCYFTLEGV | 2 | Homo sapiens, Rattus norvegicus | F215 | ERNCFFTLEGV | 1 | Bos taurus | F236 | TSAYNFDETKD | 2 | Rattus norvegicus, Bos taurus | F236 | TSIYSFDETKD | 1 | Homo sapiens | G163 | GALAAGFQHKD | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H166 | AAGFQHKDTEY | 2 | Rattus norvegicus, Bos taurus | H166 | AAGFQHKDSEY | 1 | Homo sapiens | H221 | TLEGVHEVFQE | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | I233 | GLHTSAYNFDE | 2 | Rattus norvegicus, Bos taurus | I233 | GLHTSIYSFDE | 1 | Homo sapiens | K208 | VYSDDKLERNC | 2 | Homo sapiens, Bos taurus | K208 | LYSDDKLERNC | 1 | Rattus norvegicus | K240 | SFDETKDLDLE | 1 | Homo sapiens | K240 | NFDETKDLDLD | 1 | Rattus norvegicus | K240 | NFDETKDLDLE | 1 | Bos taurus | K438 | GDYFGKEGRFE | 2 | Homo sapiens, Bos taurus | K438 | GDYFGKEGRFK | 1 | Rattus norvegicus | M337 | FEKFSMEVKSS | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | N110 | DSDCGNRALFS | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | P142 | EYAAAPVARLA | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | Q225 | VHEVFQEEGLH | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | R145 | AAPVARLASHW | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | R211 | DDKLERNCYFT | 2 | Homo sapiens, Rattus norvegicus | R211 | DDKLERNCFFT | 1 | Bos taurus | S235 | HTSAYNFDETK | 2 | Rattus norvegicus, Bos taurus | S235 | HTSIYSFDETK | 1 | Homo sapiens | T396 | QTWNRTFEGIA | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | Y138 | GPVCEYAAAPV | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | Y171 | HKDTEYSHLTR | 2 | Rattus norvegicus, Bos taurus | Y171 | HKDSEYSHLTR | 1 | Homo sapiens | Y204 | RAALVYSDDKL | 1 | Homo sapiens | Y204 | RAALLYSDDKL | 1 | Rattus norvegicus | Y204 | RAVLVYSDDKL | 1 | Bos taurus | Y214 | LERNCYFTLEG | 2 | Homo sapiens, Rattus norvegicus | Y214 | LERNCFFTLEG | 1 | Bos taurus | Y234 | LHTSAYNFDET | 2 | Rattus norvegicus, Bos taurus | Y234 | LHTSIYSFDET | 1 | Homo sapiens |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |